More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
The U.S. Department of Health and Human Services is set to release a report this month outlining possible causes of autism spectrum disorder. The Wall Street Journal reports that it names “low folate levels and acetaminophen during pregnancy” as contributing factors.
The study, which will be funded by a $2.3 million grant from the U.S. Department of Defense, will harness the power of advanced MRI technology to visualize the brain in a way that has not previously been possible.
Speaking to Vox, the authors said they were informed the results of their major study commissioned by the Department of Health and Human Services (HHS) would not be published. However, there appeared to be nothing wrong with the methodology of the analysis.
